BCAL Diagnostics Limited

BCAL Diagnostics Limited (BDX) is developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer that is safe, cost effective, accurate and available to all women regardless of age, race and geographic location. Breast cancer is the most common cancer amongst women, therefore, improving the effectiveness of the screening and diagnosis technology used is a high priority. The BCAL test is a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening and monitoring. This technology has the ability to revolutionise the breast cancer diagnostic industry. Collectively to date, BCAL analysed over 735 human plasma samples in studies undertaken in the USA and Australia. The company are in the process of validating the findings in larger cohorts and expanding to other breast cancer types. BCAL entered a clinical collaboration with RPA, Lifehouse and NSW BreastScreen to further validate the test in a real-world setting.